FISCHER35.20

Fischer Medical Ventures Limited

· Pharma & Health
₹ CrorePeersTARSONSLAXMIDENTLFABTECHGKBMcap ₹2,304 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)74.2674.26
Receivable Days (DSO)341.61341.61
Payable Days (DPO)601.69352.56
Cash Conversion Cycle (days)-185.8263.31
Working Capital Turnover1.932.30
Asset Turnover0.460.46
Cash Conversion (CFO/Net Income)-3.26-3.26
CFO/EBITDA-2.35-2.35
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.